Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AAA, absorptiometry, acquiree, al, appeal, aselagolixdisplayed, aselagolixwithout, assesselagolixagainst, AstraZeneca, auction, awaiting, bankruptcy, bipolar, bodily, Bozigian, CAC, categorized, Circuit, collapse, collateral, collateralization, comparingelagolixdrug, conveyed, counterparty, coupled, dailyelagolixarm, dayelagolix, decision, deconsolidated, Dimitri, discount, discounted, dissolved, distinguish, DMH, dual, Eastern, elagolix, elagolixtreatment, elapsed, energy, epileptic, essential, essentially, evaluateelagolixin, EvaluatePharma, expectelagolixPhase, fashion, firing, forelagolix, forelagolixin, gave, Geodon, goodwill, Haig, hedged, Hedging, hierarchy, highest, holder, Huntington, hyperkinetic, identical, illiquid, immaterial, instance, intervention, landlord, laparoscopic, Leasehold, leave, meaningful, MedAd, menstrual, month, mood, movement, network, neurotransmission, noncontrolling, nonrecurring, notification, occupy, ofelagolix, ofelagolixon, ofelagolixonce, ofelagolixto, oncology, orderly, ourelagolix, par, parent, Pharmaceutica, pivotal, plaintiff, plasma, prejudice, Pristiq, Prostap, provera, quoted, rata, rear, recurring, redeemed, redemption, renovating, renovation, rental, reset, resetting, Risperdal, SAC, schizophrenia, seizure, Seroquel, Simultaneously, SR, stabilizing, strength, student, TAC, Tardive, TaskForce, temporary, tenant, thatelagolixhad, thatelagolixmet, thenon, toxicology, tradeable, transient, transmission, transparency, transporting, Treasury, turmoil, UBS, unobservable, unprecedented, untoward, upheaval, UroToday, usage, vacated, vacating, valnoctamide, zolpidem, Zyprexa
Removed:
acceleration, accepting, advancing, affinity, allocated, Almirall, altered, Alumni, anniversary, annum, applied, balloon, bear, Bicoll, Biosite, borne, Cancer, cDNA, cell, channel, complement, construct, creation, customary, deficient, Deltagen, diabetic, expressing, fluorescent, formed, GmbH, GPCR, green, HERG, indemnify, Investor, Jack, land, lender, line, local, mandatory, Mattson, mice, owner, payroll, planning, replaced, selectivity, supported, thirty, unchanged, undertaken, University, vendor, Virginia, Wisconsin, withholding
Filing tables
Filing exhibits
Related press release
NBIX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-31791, 333-57875, 333-87127, 333-44012, 333-57096, 333-65198, 333-92328, 333-101756, 333-105907, 333-118773, 333-127214, 333-135909, 333-147120, and 333-152689) and Form S-3 (No. 333-147118) of our reports dated February 2, 2009, with respect to the consolidated financial statements of Neurocrine Biosciences, Inc., and the effectiveness of internal control over financial reporting of Neurocrine Biosciences, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2008.
/s/ Ernst & Young LLP | ||||
San Diego, California
February 2, 2009
February 2, 2009